LncAPAT promoted the macrophage inflammatory response and atherosclerotic plaque progression by inhibiting the transcriptional activity of RPL22, indicating its potential as a therapeutic target for atherosclerosis (Figure 7). This evidence concerns the gene RPL22 and atherosclerosis.